688050.SHG Eyebright Medical Technology Beijing Co Ltd
- Market cap
- CNY 8.61B
- P/E
- 35.3x
- P/B
- 2.79x
- ROE
- 11.9%
- Dividend yield
- 1.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688050.SHG undervalued?
Graham number688050.SHG trades 109.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eyebright Medical Technology Beijing Co Ltd fundamental analysis
No fundamental analysis for Eyebright Medical Technology Beijing Co Ltd yet.
Eyebright Medical Technology Beijing Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eyebright Medical Technology Beijing Co Ltd
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company provides intraocular lens, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also offers solutions for ophthalmic surgery, refractive error correction, and optometry consumption. The…
Full company profileEyebright Medical Technology Beijing Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eyebright Medical Technology Beijing Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 43.5M | 74.8M | 127M | 195M | 273M | 433M | 579M | 951M | 1.41B | 1.48B | 1.94B |
| Gross Profit | 31.1M | 56.2M | 103M | 167M | 229M | 365M | 491M | 721M | 930M | 1.48B | 1.21B |
| Operating Income | -9.85M | -3.16M | 26.8M | 69.7M | 111M | 185M | 259M | 327M | 433M | 290M | 457M |
| EBITDA | 3.50M | 6.47M | 41.9M | 92.3M | 138M | 219M | 306M | 410M | 580M | 418M | 446M |
| Net Income | -1.40M | -4.11M | 20.3M | 66.7M | 96.6M | 171M | 233M | 304M | 388M | 265M | 354M |
| EPS | -0.02 | -0.03 | 0.16 | 0.47 | 0.60 | 0.91 | 1.23 | 1.60 | 2.05 | 1.38 | 1.83 |
| Balance Sheet | |||||||||||
| Total Assets | 233M | 276M | 586M | 686M | 1.64B | 2.05B | 2.24B | 3.06B | 3.50B | 3.89B | 4.79B |
| Total Liabilities | 45.9M | 77.6M | 32.6M | 38.3M | 90.9M | 307M | 324M | 706M | 863M | 918M | 1.55B |
| Shareholders' Equity | 187M | 198M | 551M | 618M | 1.52B | 1.67B | 1.86B | 2.13B | 2.41B | 2.79B | 2.97B |
| Cash & Short-term Investments | 42.8M | 31.8M | 70.5M | 196M | 537M | 473M | 837M | 557M | 496M | 630M | 571M |
| Total Debt | 17.9M | 41.8M | 7.71M | 894K | 2.77M | 155M | 163M | 390M | 579M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.37M | 4.15M | 31.8M | 50.5M | 123M | 219M | 250M | 226M | 348M | 369M | - |
| Capital Expenditure | 27.6M | 31.5M | 71.8M | 142M | 119M | 311M | 271M | 370M | 329M | 123M | 192M |
| Free Cash Flow | -31.0M | -27.4M | -40.0M | -91.1M | 4.62M | -91.9M | -20.9M | -158M | 18.3M | 246M | 38.4M |
| Ratios | |||||||||||
| ROE | -0.7% | -2.1% | 3.7% | 10.8% | 6.4% | 10.2% | 12.5% | 14.3% | 16.1% | 9.5% | 11.9% |
| ROA | -0.6% | -1.5% | 3.5% | 9.7% | 5.9% | 8.4% | 10.4% | 9.9% | 11.1% | 6.8% | 7.4% |
| Net Profit Margin | -3.2% | -5.5% | 16.0% | 34.2% | 35.4% | 39.6% | 40.2% | 32.0% | 27.5% | 17.9% | 18.3% |
| Debt to Equity | 0.10x | 0.21x | 0.01x | 0.00x | 0.00x | 0.09x | 0.09x | 0.18x | 0.24x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eyebright Medical Technology Beijing Co Ltd dividends
- Dividend yield
- 1.04%
- Forward dividend
- 0.32 CNY
- Payout ratio
- 33.7%
- Ex-dividend date
- Jun 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 89.5M | 0.47 | 33.7% |
| 2024 | CNY 70.6M | 0.37 | 18.2% |
| 2023 | CNY 61.4M | 0.32 | 20.2% |
| 2022 | CNY 38.9M | 0.21 | 16.7% |
| 2021 | CNY 29.4M | 0.16 | 17.2% |
| 2020 | CNY 13.0K | 0.00 | 0.0% |
| 2019 | CNY 265K | 0.00 | 0.4% |
| 2018 | 819K | 0.01 | 4.0% |
| 2017 | 1.24M | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.8:1 on Jun 5, 2024.
Who owns Eyebright Medical Technology Beijing Co Ltd
- Insiders 33.32%
- Institutions 10.08%
- Public & others 56.61%
- Shares outstanding 193M
- Free float 142M
Eyebright Medical Technology Beijing Co Ltd company profile
- Company name
- Eyebright Medical Technology Beijing Co Ltd
- Ticker
- 688050.SHG
- ISIN
- CNE1000041J5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,331
- Fiscal year end
- December
- Address
- Science and Technology Park, Beijing, China, 102200
- Phone
- 86 10 6074 5730
- Website
- ebmedical.com
About Eyebright Medical Technology Beijing Co Ltd
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company provides intraocular lens, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also offers solutions for ophthalmic surgery, refractive error correction, and optometry consumption. The company was founded in 2010 and is headquartered in Beijing, China.
Eyebright Medical Technology Beijing Co Ltd management
9- Mr. Jiangbing XieChairman of the Board, GM & Chief Scientist · born 1972
- Mr. Yanchang GuoDeputy GM, CFO, Financial Director & Accounting Supervisor · born 1979
- Ms. Shaohua WangSenior VP & Director of Operations · born 1970
- Mr. Baoshan JiaDeputy GM, National Marketing & Sales Director and Director · born 1979
- Ms. Zhao WangDeputy GM, R&D Director & Director · born 1981
- Ms. Yuqian ZhouAssistant to the GM & Board Secretary · born 1987
- Ms. Shuyan GuoR&D Project Manager · born 1983
- Ms. Jie YuR&D Project Manager · born 1987
- Ms. Danxuan WangSenior Human Resources Manager · born 1982